Dicerna Pharmaceuticals, Inc.

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

Eli Lilly has seen tremendous revenue growth and become one of the most highly valued pharmaceutical companies in the world based on its GLP-1/GIP agonist tirzepatide – Mounjaro for type 2 diabetes an

Novartis has been heralding its slimmed-down, more-focused pipeline to analysts for which much of the credit goes to Shreeram Aradhye, who after a spell in US biotech returned to his roots with the

With the oft-cited patent cliff looming, big pharma companies are still looking to replenish pipelines. For many, partnering represents an important avenue to do so with its more limited financial ris